Amicus Therapeutics was a Nasdaq-listed biotechnology company focused on medicines for rare diseases. Company news centered on Galafold® (migalastat) for adults with Fabry disease who have amenable GLA variants and POMBILITI® + OPFOLDA® for adults with late-onset Pompe disease, including clinical and real-world data presentations, regulatory language, financial results, and corporate updates.
Amicus also reported investor-conference participation, operating performance, material agreements, governance matters, shareholder voting topics, and capital-structure developments. In 2026, the company completed a merger and became a wholly owned subsidiary of BioMarin Pharmaceutical Inc., making later coverage part of its corporate-status history.
Amicus Therapeutics (FOLD) announced a $400 million credit facility with Hayfin Capital Management, paving a path to profitability without future dilutive financings. The financing aims to support the company's growth in rare diseases and retire a prior term loan. The facility features a 6.5% interest rate above LIBOR, requiring interest-only payments until mid-2024, and will be fully drawn at closing. Amicus expects Galafold revenues between $250 million and $260 million for 2020, emphasizing prudent expense management and a strong financial foundation.
Amicus Therapeutics (Nasdaq: FOLD) announces that CEO John F. Crowley will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on June 10, 2020, at 8:00 a.m. ET. This event will take place virtually, allowing interested parties to access a live audio webcast via the company's Investor Relations page. Amicus Therapeutics focuses on developing innovative medicines for rare metabolic diseases, furthering its commitment to patients through a robust pipeline of advanced therapies. For details, visit www.amicusrx.com.
Amicus Therapeutics (Nasdaq: FOLD) announced the acceptance of multiple abstracts for the American Society of Gene & Cell Therapy 23rd Annual Meeting on May 12-15, 2020. The presentation includes preclinical data from the Pompe gene therapy program, alongside CLN6 and CLN8 Batten disease programs. The oral presentation is scheduled for May 14, showcasing a study on gene therapy for Pompe disease. Poster presentations will cover data on CLN6 and CLN8 Batten diseases. Pompe disease affects 5,000-10,000 people globally and is characterized by severe muscle weakness.
Amicus Therapeutics (Nasdaq: FOLD) announced acceptance of several abstracts for the American Society of Gene & Cell Therapy 23rd Annual Meeting held virtually from May 12-15, 2020. The highlights include:
- Oral Presentation: Preclinical data on Pompe gene therapy on May 14, 2020.
- Poster Presentations: Research on CLN6 Batten disease on May 12 and CLN8 Batten disease on May 13.
POMPE and Batten diseases are rare genetic disorders affecting muscle and neurological function, respectively.